Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86XE5

UPID:
HOGA1_HUMAN

ALTERNATIVE NAMES:
Dihydrodipicolinate synthase-like; Probable 2-keto-4-hydroxyglutarate aldolase; Protein 569272

ALTERNATIVE UPACC:
Q86XE5; A8K075; Q5T680; Q5T684; Q711P0; Q8N9F2; Q96EV5

BACKGROUND:
The enzyme 4-hydroxy-2-oxoglutarate aldolase, located in the mitochondria, and also referred to as Dihydrodipicolinate synthase-like, underscores its essential role in hydroxyproline metabolism by catalyzing its metabolic pathway's final step. This enzyme's activity is crucial for proper metabolic functions.

THERAPEUTIC SIGNIFICANCE:
Its association with Hyperoxaluria primary 3, characterized by symptoms such as calcium oxalate urolithiasis and hematuria, highlights the enzyme's therapeutic potential. Exploring the functions of 4-hydroxy-2-oxoglutarate aldolase could lead to innovative treatments for this genetic disorder.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.